Double Bond Pharmaceutical and Closter Pharma perform experience exchange
In week 44, i.e during 29/10 – 2/11, eight doctors from leading hospitals in Colombia will meet and exchange experiences with developers, manufacturers and users of Temodex in Belarus. During three days, they have the opportunity to be with their Belarussian colleagues and see with their own eyes how Temodex is manufactured and used on site.
"It is gratifying to meet the enthusiasm of our colleagues from Colombia and see their zeal to learn more about Temodex" -commented Igor Lokot, CEO of Double Bond Pharmaceutical. "I am proud to be part of introducing our innovative product in Latin America and look forward to continuing the process at the same high pace as so far."
More about Temodex: Temodex, which is a locally acting formulation of temozolomide developed by RI PCP in Minsk, Belarus, is registered for marketing as the first-line treatment of glioblastoma within Belarus since 2014. Temodex was acquired by DBP in autumn 2015 and is now being prepared to pass through all the tests and trials required for registration within the EU and globally. Video presentation: https://youtu.be/iweOQPq316o
More about Drugsson AB: www.drugsson.com
More about Closter Pharma: https://www.emis.com/php/company-profile/CO/Closter_Pharma_SAS_en_Reorganizacion_en_2652694.html
Full Company Name: Double Bond Pharmaceutical International AB (publ)
Corporate identity: 556991-6082
Stock short name: DBP B
Share ISIN code: SE0007185525
For more info, contact
Igor Lokot, CEO
Information on Double Bond Pharmaceutical International AB
DBP is a pharmaceutical company with the primary focus on development of therapies against cancer based on the company’s own developed drug delivery technology BeloGal®. The company was granted Orphan Drug Designation status by European Medicines Agency (EMA) in June 2015 for its first product, SA-033, for treatment of hepatoblastoma. DBP acquired rights to Temodex, a drug registered in Belarus for treatment of brain tumours, in October 2015. The company was granted Orphan Drug Designation status by EMA for Temodex in July 2016.